Paracetamol Pharmamatch (Paracetamol)

Paracetamol works by inhibiting the synthesis of prostaglandins in the central nervous system, primarily through reversible blockade of cyclooxygenase enzymes. This action reduces the perception of pain and lowers the hypothalamic set‑point for body temperature, resulting in analgesic and antipyretic effects.

The appropriate dose of Paracetamol Pharmamatch is determined by the prescribing healthcare professional based on the patient’s age, weight, clinical condition, and local regulatory guidelines. Patients should follow the prescriber’s instructions and not exceed the recommended maximum daily amount.

Safety data for paracetamol in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider before using Paracetamol Pharmamatch to weigh potential benefits against any possible risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Paracetamol offers analgesic and antipyretic benefits with a lower risk of gastrointestinal irritation compared with non‑steroidal anti‑inflammatory drugs (NSAIDs). Unlike NSAIDs, it has minimal anti‑inflammatory activity but is preferred when bleeding risk or gastric side effects are concerns.

Paracetamol Pharmamatch should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperatures to maintain its stability and potency throughout its shelf life.

Paracetamol Pharmamatch is administered orally, typically as a tablet that is swallowed whole with water. It should be taken according to the prescriber’s directions, with or without food, and the dosage interval should be observed to avoid accidental overdose.

The most serious risks include hepatotoxicity, especially with overdose or chronic high‑dose use, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they notice signs of liver injury, rash, or any allergic reaction.

Paracetamol Pharmamatch should be avoided by individuals with known hypersensitivity to paracetamol, severe liver disease, or those who have experienced serious adverse reactions to similar medications. It should also be used with caution in patients with chronic alcohol use or existing hepatic impairment.